Mirabegron
PharmaceuticalFDA ApprovedAlso known as: Myrbetriq, Betmiga, Betanis, YM-178, YM178, beta3-adrenoceptor agonist
Mirabegron is an approved prescription drug, not a research chemical. Astellas Pharma developed it as YM-178 and it was approved by the FDA in 2012 under the brand name Myrbetriq for overactive bladder, with European approval as Betmiga; the US label now also covers neurogenic detrusor overactivity in children aged three and older.
Overview
At A Glance
Mirabegron is a selective agonist of the beta-3 adrenergic receptor. In the bladder, beta-3 activation raises cyclic AMP in detrusor smooth muscle and promotes relaxation during the storage phase, which is the licensed mechanism. In adipose tissue, beta-3 stimulation drives lipol…
Overview
Mirabegron is an approved prescription drug, not a research chemical. Astellas Pharma developed it as YM-178 and it was approved by the FDA in 2012 under the brand name Myrbetriq for overactive bladder, with European approval as Betmiga; the US label now also covers neurogenic detrusor overactivity in children aged three and older. It works by activating the beta-3 adrenergic receptor, which relaxes the bladder detrusor muscle. The reason it appears on the research chemical market has nothing to do with bladders. Beta-3 receptors are also the main adrenergic receptors on rodent brown fat, and for decades beta-3 agonists were the leading candidate for a drug that would burn calories by turning on brown adipose tissue. Mirabegron was the first beta-3 agonist available in a form that could test that idea in people. The first test worked. In twelve healthy men, a single oral dose increased brown fat metabolic activity measured by FDG PET-CT in every subject and raised resting metabolic rate by 203 kcal per day, about 13 percent (PMID: 25565203). A four-week open-label study in 14 healthy women found higher brown fat activity and resting energy expenditure with no change in body weight or composition, alongside higher HDL cholesterol, apolipoprotein A-I, adiponectin and improved insulin sensitivity on an intravenous glucose tolerance test (PMID: 31961826). The complication is dose and receptor selectivity. A Canadian group showed that human brown adipocyte thermogenesis is actually driven by the beta-2 receptor, not beta-3, and that mirabegron only raised brown fat thermogenesis when taken at the maximum allowable dose, at which point it also bound beta-1 and beta-2 receptors, producing cardiovascular effects and white fat lipolysis (PMID: 32755608). A meta-analysis of six human studies found increased brown fat activity, resting energy expenditure, body temperature and free fatty acids, but also increased heart rate, diastolic blood pressure and insulin, with no change in brown fat volume or blood glucose (PMID: 38159219). Pharmacology is well characterized because it is a licensed drug. Plasma concentrations peak at three to five hours and decline with a terminal half-life of roughly 32 to 60 hours across two phase 1 studies; exposure is about 40 percent higher in women than men, and steady state is reached within a week (PMID: 23063375). Absorption, metabolism and excretion have been mapped with radiolabeled drug (PMID: 22269146). Anyone taking mirabegron for metabolic reasons is using an approved drug off-label at or near its ceiling dose, where the cardiovascular effects are real and measured. That is a different risk profile from its licensed bladder use, and it needs a prescriber, not a supplier.
Potential Research Fields
Chemical Information
IUPAC Name
Not yet available
CAS Number
223673-61-8
Molecular Formula
C21H24N4O2S
Molecular Mass
396.51 g/mol
Dosing & Protocols
Unlock Dosing Protocols
Free account gets you:
- View beginner, intermediate & advanced protocols
- See weight-based dosing calculations
- Access cycle length & frequency data
2,800+ researchers already in
Research
Unlock Research Data
Free account gets you:
- Browse PubMed study summaries
- See clinical trial phases & results
- Access mechanism of action details
2,800+ researchers already in
Interactions
Contraindications
Label-based and mechanism-based: the approved product labeling should be consulted, and the documented rises in heart rate and blood pressure make uncontrolled hypertension a clear concern for off-label metabolic use (PMID: 38159219). Exposure is about 40 percent higher in women than in men, which matters for dosing decisions made by a prescriber (PMID: 23063375). Mirabegron inhibits CYP2D6, so interactions with CYP2D6 substrates such as desipramine and metoprolol are documented and require prescriber review. Off-label use for fat loss has not been studied beyond four weeks.
Research Disclaimer
This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds.
$99.99
$0.0333
1
1
capsule
| Vendor | Product | Form | Qty | Price | $/mg | Coupon | |
|---|---|---|---|---|---|---|---|
 |
Mirabegron 50 mg capsules (60) | capsule | 60 capsules (50 mg)● In Stock | $99.99BEST | $0.033 | — |
Tracking since Sep 7, 2026 · 1 data point
Vendors Selling Mirabegron
How we score these vendors
Every supplier above is graded 0–100 on COA verification, payment transparency, shipping, reviews, and active listings. Methodology published, no pay-to-rank.
Related Compounds
View AllAlbuterol (salbutamol)
PharmaceuticalFDA ApprovedAlbuterol, called salbutamol outside the United States, is a beta-2 adrenergic agonist and a standard asthma medicine worldwide.
Clascoterone
PharmaceuticalPreclinicalClascoterone (brand name Winlevi; development codes CB-03-01 and, for the alopecia formulation, Breezula) is a first-in-class topical androgen receptor (AR) antagonist approved by the U.S.
Finasteride
PharmaceuticalPreclinicalFinasteride is an orally-active selective type II 5α-reductase inhibitor that blocks the conversion of testosterone to dihydrotestosterone (DHT), the primary androgenic driver of both benign prostatic hyperplasia (BPH) and androgenetic alopecia (male-pattern hair loss).
Meldonium
PharmaceuticalApproved (Latvia)Meldonium, sold as Mildronate, was developed at the Latvian Institute of Organic Synthesis (PMID: 12242052) and is a licensed cardiovascular medicine in Latvia and a number of eastern European and post-Soviet countries.
Tropisetron
PharmaceuticalApproved (Japan)Tropisetron, coded ICS 205-930 during development and marketed as Navoban, is a serotonin 5-HT3 receptor antagonist approved as an antiemetic in Japan and in many other countries outside the United States, with ATC code A04AA03 (KEGG DRUG D02041, D02130).
View Full Dosage Guide →
Protocols, calculator & safety for Mirabegron
Research Score
0 PubMed studies
Quality Indicators
Data Completeness
63%Quick Facts
Half-Life
Terminal half-life about 32 hours in one phase 1 multiple-dose study and about 60 hours in a second, with plasma peaks at three to five hours and steady state within seven days in healthy young and elderly adults (PMID: 23063375)
Molecular Weight
396.51 g/mol
Administration
Oral
CAS Number
223673-61-8
Trial Phase
FDA Approved
Research Disclaimer
This information is for educational and research purposes only. Not intended as medical advice. Consult a healthcare professional before use.
Frequently Asked Questions
What is Mirabegron used for in research?
Mirabegron is an approved prescription drug, not a research chemical. Astellas Pharma developed it as YM-178 and it was approved by the FDA in 2012 under the brand name Myrbetriq for overactive bladder, with European approval as Betmiga; the US label now also covers neurogenic detrusor overactivity in children aged three and older. It works by activating the beta-3 adrenergic receptor, which relaxes the bladder detrusor muscle.
The reason it appears on the research chemical market has nothing to do with bladders. Beta-3 receptors are also the main adrenergic receptors on rodent brown fat, and for decades beta-3 agonists were the leading candidate for a drug that would burn calories by turning on brown adipose tissue. Mirabegron was the first beta-3 agonist available in a form that could test that idea in people.
The first test worked. In twelve healthy men, a single oral dose increased brown fat metabolic activity measured by FDG PET-CT in every subject and raised resting metabolic rate by 203 kcal per day, about 13 percent (PMID: 25565203). A four-week open-label study in 14 healthy women found higher brown fat activity and resting energy expenditure with no change in body weight or composition, alongside higher HDL cholesterol, apolipoprotein A-I, adiponectin and improved insulin sensitivity on an intravenous glucose tolerance test (PMID: 31961826).
The complication is dose and receptor selectivity. A Canadian group showed that human brown adipocyte thermogenesis is actually driven by the beta-2 receptor, not beta-3, and that mirabegron only raised brown fat thermogenesis when taken at the maximum allowable dose, at which point it also bound beta-1 and beta-2 receptors, producing cardiovascular effects and white fat lipolysis (PMID: 32755608). A meta-analysis of six human studies found increased brown fat activity, resting energy expenditure, body temperature and free fatty acids, but also increased heart rate, diastolic blood pressure and insulin, with no change in brown fat volume or blood glucose (PMID: 38159219).
Pharmacology is well characterized because it is a licensed drug. Plasma concentrations peak at three to five hours and decline with a terminal half-life of roughly 32 to 60 hours across two phase 1 studies; exposure is about 40 percent higher in women than men, and steady state is reached within a week (PMID: 23063375). Absorption, metabolism and excretion have been mapped with radiolabeled drug (PMID: 22269146).
Anyone taking mirabegron for metabolic reasons is using an approved drug off-label at or near its ceiling dose, where the cardiovascular effects are real and measured. That is a different risk profile from its licensed bladder use, and it needs a prescriber, not a supplier.
What forms does Mirabegron come in?
Mirabegron is available in capsule form.
How much does Mirabegron cost?
Prices start at $99.99 across 1 verified vendor.
How do I compare Mirabegron vendors?
Compare prices, payment methods, shipping, and COA scores across 1 vendor.
Research Tools
Related Compounds
View AllAlbuterol (salbutamol)
PharmaceuticalFDA ApprovedAlbuterol, called salbutamol outside the United States, is a beta-2 adrenergic agonist and a standard asthma medicine worldwide.
Clascoterone
PharmaceuticalPreclinicalClascoterone (brand name Winlevi; development codes CB-03-01 and, for the alopecia formulation, Breezula) is a first-in-class topical androgen receptor (AR) antagonist approved by the U.S.
Finasteride
PharmaceuticalPreclinicalFinasteride is an orally-active selective type II 5α-reductase inhibitor that blocks the conversion of testosterone to dihydrotestosterone (DHT), the primary androgenic driver of both benign prostatic hyperplasia (BPH) and androgenetic alopecia (male-pattern hair loss).
Meldonium
PharmaceuticalApproved (Latvia)Meldonium, sold as Mildronate, was developed at the Latvian Institute of Organic Synthesis (PMID: 12242052) and is a licensed cardiovascular medicine in Latvia and a number of eastern European and post-Soviet countries.
Tropisetron
PharmaceuticalApproved (Japan)Tropisetron, coded ICS 205-930 during development and marketed as Navoban, is a serotonin 5-HT3 receptor antagonist approved as an antiemetic in Japan and in many other countries outside the United States, with ATC code A04AA03 (KEGG DRUG D02041, D02130).
Free 2026 Peptide Cheat Sheet — 50 pages, PDF
Reconstitution math, concentration charts, half-lives, and vendor trust tiers. The reference we wish we had on day one.